Los Angeles Capital Management
IBRX icon

Los Angeles Capital Management’s ImmunityBio IBRX Stock Holding History

Los Angeles Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.3K Sell
3,292
-128,956
-98% -$883K ﹤0.01% 1678
2025
Q4 		$312K Buy
+132,248
New +$300K ﹤0.01% 1080
2022
Q2 		– Sell
-64,030
Closed -$359K – 1385
2022
Q1 		$359K Hold
64,030
– – ﹤0.01% 1171
2021
Q4 		$389K Buy
+64,030
New +$481K ﹤0.01% 1124

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Los Angeles Capital Management's IBRX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its ImmunityBio (IBRX) stake by 98% in Q1 2026, selling an estimated $883K and leaving 3,292 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Los Angeles Capital Management first reported a position in IBRX in Q4 2021 and has held it in 4 quarters since. The position peaked at $389K in Q4 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Los Angeles Capital Management held 3,292 shares of ImmunityBio worth $25.3K as of Q1 2026.
  • Los Angeles Capital Management sold 128,956 ImmunityBio shares in Q1 2026, an estimated $883K.
  • ImmunityBio made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1678 holding.
  • Los Angeles Capital Management first reported a position in ImmunityBio in Q4 2021 and has held it in 4 quarters since.
  • Los Angeles Capital Management's ImmunityBio position peaked at $389K in Q4 2021.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.